Loading
Latest filing published 29 Jul 2026 for Outlook Therapeutics, Inc., €88k.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Faisal Ghiath Sukhtian in Outlook Therapeutics, Inc., where the filings describe the role as board member. Between 17 September 2020 and 29 July 2026, the trades on record add up to 6 filings.
No open-market sale appears; the market trades are 5 purchases worth €170k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2026 alone, the filings show 1 purchase and no sales.
In size, the median ticket on the buying side is €22k. On 4 out of 5 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The newest entry dates from 29 July 2026: an open-market purchase of €88k, in Outlook Therapeutics, Inc. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations